Tumour Cell Heterogeneity.

A divide-and-conquer strategy in tumor sampling enhances detection of intratumor heterogeneity in routine pathology: A modeling approach in clear cell renal cell carcinoma. F1000Res (2016) 0.88

A multi-site cutting device implements efficiently the divide-and-conquer strategy in tumor sampling. F1000Res (2016) 0.83

Variant CD44 expression is enriching for a cell population with cancer stem cell-like characteristics in human lung adenocarcinoma. J Cancer (2017) 0.75

Cell adhesion heterogeneity reinforces tumour cell dissemination: novel insights from a mathematical model. Biol Direct (2017) 0.75

Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56

The clonal evolution of tumor cell populations. Science (1976) 24.39

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med (2009) 22.23

Tumour evolution inferred by single-cell sequencing. Nature (2011) 19.13

Fibroblasts in cancer. Nat Rev Cancer (2006) 18.95

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69

Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72

Rates of spontaneous mutation. Genetics (1998) 14.89

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33

Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29

Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39

Cancer as an evolutionary and ecological process. Nat Rev Cancer (2006) 9.33

Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25

A restricted cell population propagates glioblastoma growth after chemotherapy. Nature (2012) 8.88

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77

Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature (2010) 8.48

Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol (2005) 8.15

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature (2012) 8.13

Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat Biotechnol (2011) 7.84

Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell (2011) 7.30

Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23

Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82

Clonal architecture of secondary acute myeloid leukemia. N Engl J Med (2012) 6.71

Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet (2006) 6.71

Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell (2011) 6.43

Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet (2012) 6.25

Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science (2014) 6.09

Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol (2002) 5.75

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet (2014) 5.74

Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A (2013) 5.68

Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science (2014) 5.63

Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science (2012) 4.92

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature (2013) 4.90

Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell (2012) 4.58

Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science (2013) 4.42

Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science (2014) 4.28

Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest (2010) 4.22

How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer (2010) 4.19

Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature (2014) 4.13

Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell (2006) 4.07

A Big Bang model of human colorectal tumor growth. Nat Genet (2015) 3.77

The evolutionary history of lethal metastatic prostate cancer. Nature (2015) 3.59

Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res (1994) 3.25

Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med (2012) 3.21

A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. Lancet Oncol (2015) 3.17

The fidelity of DNA synthesis by eukaryotic replicative and translesion synthesis polymerases. Cell Res (2008) 3.15

Replication stress links structural and numerical cancer chromosomal instability. Nature (2013) 3.11

Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature (2014) 2.91

Adaptive therapy. Cancer Res (2009) 2.81

Interaction between Ras(V12) and scribbled clones induces tumour growth and invasion. Nature (2010) 2.79

Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature (2014) 2.79

Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer (2011) 2.77

Evolutionary dynamics of cancer in response to targeted combination therapy. Elife (2013) 2.76

Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76

Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature (2014) 2.75

Evolution of cooperation among tumor cells. Proc Natl Acad Sci U S A (2006) 2.63

Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer (2013) 2.56

Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. Sci Transl Med (2012) 2.55

Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. Gut (2008) 2.51

Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol (2013) 2.35

Quiescent sox2(+) cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma. Cancer Cell (2014) 2.30

Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet (2015) 2.29

Polyclonal origin of colonic adenomas in an XO/XY patient with FAP. Science (1996) 2.22

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med (2015) 2.12

Tumor heterogeneity and permeability as measured on the CT component of PET/CT predict survival in patients with non-small cell lung cancer. Clin Cancer Res (2013) 2.08

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res (2014) 2.03

Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet (2013) 1.93

A change of strategy in the war on cancer. Nature (2009) 1.92

A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res (Phila) (2010) 1.89

Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology (2014) 1.84

Clonality assessment and clonal ordering of individual neoplastic crypts shows polyclonality of colorectal adenomas. Gastroenterology (2010) 1.83

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med (2014) 1.79

Oncogene-like induction of cellular invasion from centrosome amplification. Nature (2014) 1.72

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann Oncol (2014) 1.64

Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med (2015) 1.64

Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol (2007) 1.61

Evolutionary biology of cancer. Trends Ecol Evol (2005) 1.58

G&T-seq: parallel sequencing of single-cell genomes and transcriptomes. Nat Methods (2015) 1.56

Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments. Transl Oncol (2008) 1.51

Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet (2015) 1.47

Replication stress and cancer. Nat Rev Cancer (2015) 1.43

High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer (2013) 1.43

Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.38

Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus. Cancer Prev Res (Phila) (2013) 1.31

The clonal evolution of metastases from primary serous epithelial ovarian cancers. Int J Cancer (2009) 1.29

Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proc Natl Acad Sci U S A (2015) 1.29

Tumorigenesis: it takes a village. Nat Rev Cancer (2015) 1.27

Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep (2014) 1.27

Identification of neutral tumor evolution across cancer types. Nat Genet (2016) 1.25

Exploiting evolution to treat drug resistance: combination therapy and the double bind. Mol Pharm (2012) 1.22

Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast (2011) 1.21

Mismatch repair genes on chromosomes 2p and 3p account for a major share of hereditary nonpolyposis colorectal cancer families evaluable by linkage. Am J Hum Genet (1994) 1.18

Turning ecology and evolution against cancer. Nat Rev Cancer (2014) 1.15

Impact of metabolic heterogeneity on tumor growth, invasion, and treatment outcomes. Cancer Res (2015) 1.12

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts. EMBO Mol Med (2015) 1.11

Spatial structure increases the waiting time for cancer. New J Phys (2011) 1.02

Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale. Curr Opin Genet Dev (2014) 1.01